novo nordisk glp-1 receptor agonist medications Novo, Lilly buoyed by fast-growing drug sales GLP-1 RA education
Description
10.1038/s41573-020-00135-8 69 NevolaR.EpifaniR.ImbrianiS.TortorellaG.ApreaC.GalieroR.et al (2023)
Med Hypotheses
The most common adverse events are nausea and other gastrointestinal discomfort
Initially approved for T2D management, GLP-1 RAs have also demonstrated cardiovascular and renal benefits [5,6,7]
